Often, medicinal development has focused on minute agents, but peptidic collaborations are progressively demonstrating momentum. This innovative strategy involves combining peptidic sequences with complementary medicinal modalities to confront challenging disease pathways. By employing the distinctive features of peptides – such as substantial se